Pfizer's biosimilar to Remicade is expected to be available in pharmacies by the end of November.
Just the second biosimilar to launch in the United States, Pfizer has said that Inflectra (infliximab-dyyb)—biosimilar to Johnson & Johnson’s Remicade (infliximab)—will cost 15% less than the list price of the reference product. In an associated press release, the company announced that the drug will be available to US wholesalers in late November.
Inflectra was approved early this year for patients with rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, and plaque psoriasis. A single dose of Remicade can cost anywhere between $1300 and $2500 without insurance, depending on a variety of factors such as the person’s weight, the immune disorder being treated, and whether it is an active treatment or a maintenance dose. Pfizer’s pricing, however, does not consider discounts to health plans, distributors, or other purchasing organizations.
“By introducing Inflectra to the US marketplace, Pfizer is helping customers access an additional high-quality treatment option that promises greater savings for the healthcare system,” Diem Nguyen, regional president North America, Pfizer Essential Health Business, said in a statement. “We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high quality, consistent supply of product and long-term savings and value for patients and physicians.”
In reaction to this announcement, J&J said in a statement that it will compete with the price of Inflectra “through a variety of innovative contracting options, discounts and rebates to payers, providers, and pharmacy benefit managers.” In an e-mail to Reuters, J&J said that this would be an “at-risk launch” considering its ongoing litigations against Pfzer. If Pfizer is found guilty of having infringed Remicade patents, J&J would be entitled to triple damages.
Biosimilars are still in an infant stage in the US healthcare market, and patients and physicians remain wary about using them. According to a JP Morgan analyst, the 15% discount on Inflectra could attract new patients but may fall short of enticing those on Remicade to switch.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Study Finds Link Between Depression, Functional Impairment in Psoriasis, Psoriatic Arthritis
November 24th 2023Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.
Read More
Evaluating Work Productivity, Efficacy and Safety of Tildrakizumab in Patients With Plaque Psoriasis
November 13th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.
Read More
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More